menu search

IKNA / Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. Read More
Posted: Jun 20 2023, 10:16
Author Name: Zacks Investment Research
Views: 102622

IKNA News  

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

By Zacks Investment Research
June 20, 2023

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the more_horizontal

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
June 2, 2023

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the more_horizontal

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

By Zacks Investment Research
May 5, 2023

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisi more_horizontal

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 14, 2023

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the n more_horizontal

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

By GlobeNewsWire
March 7, 2022

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-direct more_horizontal


Search within

Pages Search Results: